Vectura Group plc Notice of Results (9372W)
February 15 2017 - 4:00AM
UK Regulatory
TIDMVEC
RNS Number : 9372W
Vectura Group plc
15 February 2017
Vectura Group plc
Notice of Preliminary Results
Chippenham, UK, 15 February 2017: Vectura Group plc (LSE: VEC)
("the Group"), an industry-leading inhaled airways disease focused
business, plans to announce its Preliminary Results for the nine
month period ended 31 December 2016 on Tuesday 21 March 2017.
James Ward-Lilley, Chief Executive Officer, and Andrew Derodra,
Chief Financial Officer, will host a briefing for analysts at
9.30am on the morning of results in the Guildhall Room, 85 Gresham
Street, London, EC2R 7HE.
A live webcast of the meeting, with the presentation slides,
will be made available on Vectura's website:
http://www.vectura.com/investors/presentations-webcasts/.
- ENDS -
Enquiries
Vectura Group plc +44 (0)1249 667700
Andrew Derodra - Chief Financial Officer
Fleur Wood - Director Communications
Elizabeth Knowles - Director Investor Relations and Analysis
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange
(LSE: VEC), is an industry-leading inhaled airways disease focused
business with proprietary formulation and devices across DPI, pMDI
and "smart" nebulisation platforms. With our extensive range of
technologies, capabilities and collaborations, we believe we can
become a leader in the development of inhalation products,
increasing our ability to help patients suffering from respiratory
diseases. In June 2016 Vectura completed a merger with Skyepharma
PLC.
Vectura has seven inhaled, four non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a portfolio of drugs in clinical development, a number of which
have licence agreements with several global pharmaceutical and
biotechnology companies including Hikma, Novartis, Sandoz,
Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi,
Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at
www.vectura.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLIFSTFLIELID
(END) Dow Jones Newswires
February 15, 2017 04:00 ET (09:00 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024